What is the clinical evidence from this study?

Study design: Observational. Population: Deep Vein Thrombosis (n=40). Intervention: Clopidogrel + Apixaban vs. Aspirin + Rivaroxaban. Primary outcome: Incidence of DVT recurrence and progression (p=0.0035 for recurrence, p=0.0035).

What question did this study set out to answer?

This research evaluates the safety and effectiveness of Aspirin-Rivaroxaban and Clopidogrel-Apixaban in preventing DVT recurrence.

February 26, 2026Open Access

Comparative Study on the Safety and Efficacy of Aspirin plus Rivaroxaban vs Clopidogrel plus Apixaban in Deep Vein Thrombosis Patients

Key Result

Clopidogrel plus Apixaban reduced DVT recurrence to 5% compared to 45% with Aspirin plus Rivaroxaban (p=0.0035) in patients with DVT over one year.

Key Points

This research evaluates the safety and effectiveness of Aspirin-Rivaroxaban and Clopidogrel-Apixaban in preventing DVT recurrence.
Conducted a forward-looking observational study with 40 participants diagnosed with DVT.
Participants were evenly allocated between two treatment groups: Aspirin-Rivaroxaban and Clopidogrel-Apixaban.
Assessed parameters included DVT recurrence, progression, bleeding events, death rates, and laboratory markers.
Data analysis used Chi-square and T-tests with SPSS v26.0.
The CA group showed a significantly lower DVT recurrence rate (5% vs. 45%; p=0.0035).
Tendency towards less disease progression in CA group (10% vs. 35%; p=0.051).
No significant differences in major/mild hemorrhage and fatality rates between groups.
Baseline INR, haemoglobin, and platelet count were significantly different from the normal range (p<0.05).

Study Design

Type

Observational (n=40)

Multicenter

Structured PICO

Does Apixaban plus Clopidogrel reduce DVT recurrence and progression compared to Rivaroxaban plus Aspirin in patients with Deep Vein Thrombosis?

Population

40 patients aged 18 and older with confirmed Deep Vein Thrombosis (DVT). Exclusions: bleeding disorders, pregnant women, and patients with severe hepatic/renal disorders.

Intervention

Apixaban 5 mg twice daily plus Clopidogrel 75 mg once daily

Comparator

Rivaroxaban 20 mg once daily plus Aspirin 100 mg once daily

Outcome

Incidence of DVT recurrence and progressionhard clinical

In patients with DVT, a combination of Clopidogrel and Apixaban significantly reduced DVT recurrence compared to Aspirin and Rivaroxaban without a significant increase in bleeding, though baseline imbalances limit the strength of these findings.

Main Result

Effect estimate: p=0.0035 for recurrence

Absolute Event Rate: 5% vs 45%

p-value: p=0.0035

Limitations

Small sample size of 40 participants
Observational study design without randomization
Limited follow-up duration of one year

Abstract

Background: This research aims to evaluate and contrast the effectiveness and safety profiles of Aspirin with Rivaroxaban (RA) and Clopidogrel with Apixaban (CA) in minimizing thromboembolic risks among patients diagnosed with Deep Vein Thrombosis (DVT). Methodology: A forward-looking observational study was conducted involving 40 participants with confirmed DVT, allocated evenly between two treatment groups. Parameters assessed included recurrence and progression of DVT, bleeding events, death rates, and relevant laboratory markers. Data analysis involved Chi-square and T-tests using SPSS v26.0. Findings: The patients in the CA group had a significantly lower rate of DVT recurrence (5% vs. 45%; p= 0.0035) and a tendency towards less disease progression (10% vs. 35%; p = 0.051). The incidence of major and mild hemorrhage, as well as fatality rates, did not exhibit significant differences. However, the baseline INR, haemoglobin, and platelet count were significantly different (p<0.05) from the normal range. Conclusion: Clopidogrel-apixaban seemed to be more effective in the prevention of DVT recurrence without increasing the risk to the patients’ safety compared to Aspirin-Rivaroxaban. This study needs to be followed by broader, randomised trials to confirm these findings.

Bookmark

View Full Paper